CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
We received an updated WNV package insert; please note the manufacturer and license number has been ...